The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV.
The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV.
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
-
Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 30333
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Centers for Disease Control and Prevention,
Agam Rao, MD, PRINCIPAL_INVESTIGATOR, Centers for Disease Control and Prevention
Irini Sereti, MD, STUDY_DIRECTOR, National Institutes of Health (NIH)
Faisal Minhaj, Pharm.D., STUDY_DIRECTOR, Centers for Disease Control and Prevention
Shama Cash-Goldwasser, MD, STUDY_DIRECTOR, Centers for Disease Control and Prevention
Jesse OShea, MD, STUDY_DIRECTOR, Centers for Disease Control and Prevention
Christine Hughes, PhD, STUDY_DIRECTOR, Centers for Disease Control and Prevention
Brian Epling, MD, STUDY_DIRECTOR, National Institutes of Health (NIH)
Katy Saliba, PhD, STUDY_DIRECTOR, National Institutes of Health (NIH)
Jason Zucker, MD, STUDY_DIRECTOR, Columbia University
Sarah Reagan Steiner, MD, STUDY_DIRECTOR, Centers for Disease Control and Prevention
Sarah Park, MD, STUDY_DIRECTOR, Karius Laboratories
2024-10-01